USPTO serial 97106183
EXOTAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 30, 2024
- Examiner
- DWYER, JOHN D
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EXOTAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Janice Housey
Janice Housey Litmus Law PLLC4 Weems Lane #240Winchester, VA 22601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; biological preparations for use in experiments containing exosomes carrying the desired protein, other than for medical or veterinary use; biochemical preparations for gene recombination for scientific or laboratory purposes; biological tissue cultures, other than for medical or veterinary purposes; cells for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents for use in biological or genetic engineering for scientific or research use and medical laboratory use; reagents for scientific or medical research use; biological preparations for use in biotechnology industry and science, other than for medical purpose; cell growth media for growing cells for use in scientific research; biochemicals for in vitro and in vivo scientific use; reagents for medical research; biological preparation containingexosomes for use in manufacture of cosmetics; protein for use in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics; proteins for the food industry | ACTIVE | — |
| 005 | Biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical preparations for medical or veterinary purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceuticals featuring drug delivery system, namely, pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary diseases; preparations for intracellular drug delivery, namely, drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injections, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations; pharmaceuticals for the treatment of immune system disease; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cellular diseases; chemico-pharmaceutical preparations for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; protein preparations, namely, protein supplements; biotechnological preparations for medical purposes for treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; reagents for medical use; pharmaceuticals for human purposes for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biochemical pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases; biological tissue cultures for medical purposes; diagnostic reagents for medical use; pharmaceuticals for the treatment of cancer, metabolic diseases, inflammatory diseases, genetic diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, auto-immune diseases, fibrosis diseases, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, and urinary diseases | ACTIVE | — |
| 042 | Research and development of technology for biotechnology; development of pharmaceutical preparations and medicines; development of cell therapy products; research and development of new pharmaceuticals; medical research and product development services; research and development of vaccines and medicines; product development in the field of biologics; research of biologics, namely, scientific study and research in the field of biologics; laboratory research in the field of biology; industrial research in the field of biomedical engineering; technological research in the field of cell biology; scientific research in the field of pharmaceuticals; biotechnology research; biological research services; research for medical products; research in the field of chemistry; drug discovery services; biomedical research services; pharmaceutical drug development services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ILIAS Biologics Inc.
- Other trademarks owned by ILIAS Biologics Inc.
- Other trademarks owned by ILIAS Biologics Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named EXOTAC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 16, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 16, 2026 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Mar 16, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 30, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 14, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 11, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 11, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 11, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2024 | ALIE | ASSIGNED TO LIE | — |
| Nov 18, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 11, 2023 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Sep 11, 2023 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Sep 11, 2023 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Mar 14, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 14, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 14, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 18, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 18, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 13, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 6, 2021 | NWAP | NEW APPLICATION ENTERED | — |